Similar to findings from the global CAPItello-291 population [16], analysis in the Japan subgroup of patients with confirmed PIK3CA/AKT1/PTEN-non-altered tumors suggests that the addition of capivasertib to fulvestrant exerts a PFS benefit regardless of the presence of PIK3CA/AKT1/PTEN tumor alterations, although hazard ratios suggest benefit is less pronounced. This evidence concerns the gene PIK3CA and neoplasm.